Innovation Zed Expands Research Project Evaluating a Non-Invasive Glucose Monitoring System

Innovation Zed Expands Research Project Evaluating a Non-Invasive Glucose Monitoring System

Innovation Zed Ltd, which is focused on developing technologies to improve the health and quality of life for individuals living with diabetes, today announced the expansion of a research project evaluating a non-invasive Continuous Glucose Monitoring (CGM) system.

The monitoring of glucose fluctuations is a vital aspect for the acute control of diabetes and improved long term health outcomes, making it a significant component in the daily life of people with diabetes. Commercial BGM (blood glucose monitoring) systems require a finger prick whilst current CGM systems require the insertion of a filament underneath the skin, resulting in small wounds that can cause pain and infections.

With funding under the Irish Research Council’s Enterprise Partnership Scheme, Innovation Zed, a NovaUCD client company, is collaborating with University College Dublin (UCD), on a research project focused on advancing a non-invasive, multi-sensor approach to recording acute changes in the blood glucose levels of people living with diabetes.

Dr Dean Minnock, CEO, Innovation Zed, “We pride ourselves on taking on complex technological challenges with our sole aim of easing the stresses caused by diabetes. There is a clear need for alternative options for monitoring glucose levels which should be non-invasive, painless, discreet, and easy to use. This project is a further step in the right direction and through this collaboration we are advancing our research into a non-invasive CGM system.”

Dr Rui Wu, a post-doctoral research fellow in the UCD School of Electrical and Electronic Engineering is the lead researcher on this project and is being supported in this project by Professor Madeleine Lowery, UCD School of Electrical and Electronic Engineering.

"I am delighted to be involved in this project and to be working with Innovation Zed on this fascinating project. This area of research is something I am extremely passionate about, and I greatly appreciate having the opportunity to lead this challenging project is and to drive it in a new direction," said Dr Wu.

Innovation Zed has already brought to market various technologies to support multiple daily injection (MDI) insulin users with add-on technology that automatically collects essential usage data that informs insulin pen users of their injection history and trends under the “InsulCheck” brand.

Dr Minnock added, “This project is the latest addition to several exciting projects being undertaken by Innovation Zed This is also the first of many fascinating announcements we will be making over the next 12 months. Our strategy of bringing cutting edge diabetes management technologies to a wider audience is advancing strongly, and we are constantly improving on our portfolio of offerings.”


11 October 2021

For more information contact Micéal Whelan, Communications and Media Relations Manager, NovaUCD, e: or Dean Minnock, CEO, Innovation Zed, e:

Editors Notes

Innovation Zed designs connected health solutions that support drug adherence and Condition Management. As technologies continue to evolve, it opens new and exciting possibilities for connected healthcare to deliver increased freedom and control to patients. That is why Innovation Zed is actively developing and researching new methods to improve drug adherence and optimise treatment to enable more personalised condition management.

At NovaUCD, the hub for new ventures and entrepreneurs at University College Dublin, we nurture and support new high-tech and knowledge-intensive companies as part of UCD's mission. At NovaUCD we provide purpose-built, state-of-the-art incubation facilities alongside a comprehensive business support programme for client companies such as Innovation Zed. NovaUCD has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, UCD and Xilinx.